Operator: And our next question today comes from A.J. Rice at Credit Suisse.
A.J. Rice : Just to circle back to couple of things on the Medicaid reverifications. Obviously, it’s sort of a herculean task for the states to go through this process. It seems like everyone involved. Is it having any impact? It doesn’t seem like it — but I’ll ask the question on either RFPs working through the system or RFPs that are being awarded, be it stood up? Have you seen any spillover impact on any of that? And then just a follow-up on Drew’s comment on the acuity adjustments. Just give us the latest thinking on how quickly those acuity adjustments may happen as data rolls in? And are there any states that are saying, “Hey, we’ll help you out prospectively anticipating some change?”
Sarah London : Yes. Thanks, A.J. I’ll let Drew talk about the rates, but it is important just to — as a reminder, that we saw — we have a number of states that had a 7/1 renewal and had very constructive conversations. All of those states have included acuity adjustments. And we’re seeing that trend carry forward, but I’ll let him get specific on that. Relative to the overall Medicaid redeterminations landscape, you are right that this is sort of an unprecedented scale of effort. And we’ve been really pleased with the level of partnership that we’ve seen the states and in general, a trend that states are leaning in to the value of public-private partnership that we offer. But Ken’s been out talking with our Medicaid directors and our governors very closely over the last weeks and months. So I’ll let him provide a little bit more color on that, and then kick it over to Drew to just talk a bit about the rate discussions.
Ken Fasola: Yes. Thanks, A.J. In fact, we were with nearly 14 governors last week, had an opportunity to spin through the Republican Governors Association. And in every conversation we had, redeterminations came up with an eye towards, one, what are we seeing by virtue of the view we have across multiple markets, best methods and genuine appreciation for opportunity that’s available to provide more informed counsel to members throughout reach. Sarah mentioned the millions of interactions that we’ve had, the collaboration with the departments, clearly an eye towards doing the best to give members a chance to make an informed decision. And when there’s procedural disenrollments to move quickly to provide the opportunity to get those folks either into the right spot, whether it’s in Medicaid or we’re seeing opportunities in the Marketplace.
Finally, to your point about whether it’s going to slow the pipeline, there’s no indication of that with respect to procurement and reprocurements. Drew?
Drew Asher: Yes, A.J., on acuity, over the — really, over the past year, we’ve been putting data in front of our state partners and working collaboratively with them and their actuaries in anticipation of the commencement of redeterminations. So often, really on behalf of all the payers in the Marketplace in Medicaid, we’re working with the state and the associations to influence for what we think is appropriate in terms of not just rates, but the acuity component within rates. And then by definition, the 7/1 rate increases, and we sold two outstanding between 7/1 and 10/1, but the 12 that we’ve gotten so far, all of which have had acuity adjustments with a focus on the redetermination impact. By definition, those are prospective, except for maybe the couple of months that we have under our belt so far in redeterminations. So pretty pleased with the partnership with our state partners. And plenty of work to do, A.J., but it’s a good start.
Operator: And our next question today comes from Kevin Fischbeck, Bank of America.
